×

Message

EU e-Privacy Directive

This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.

View e-Privacy Directive Documents

You have declined cookies. This decision can be reversed.

Novel concepts of neuropeptide-based drug therapy: Vasoactive intestinal polypeptide and its receptors

David A. Groneberga, b,  ,  , Klaus F. Rabec and Axel Fischera
aDepartment of Respiratory Medicine, Hannover Medical School, Hannover, Germany
bAllergy-Centre-Charité, Charité — Universitätsmedizin Berlin, Free University Berlin and Humboldt-University, Berlin, Germany
cDepartment of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands
Accepted 13 December 2005.
Available online 10 February 2006.

Abstract
Chronic inflammatory airway diseases such as bronchial asthma or chronic obstructive pulmonary disease (COPD) are major contributors to the global burden of disease. Although inflammatory cells play the central role in the pathogenesis of the diseases, recent observations indicate that also resident respiratory cells represent important targets for pulmonary drug development. Especially targeting airway neuromediators offers a possible mechanism by which respiratory diseases may be treated in the future.

Among numerous peptide mediators such as tachykinins, calcitonin gene-related peptide, neurotrophins or opioids, vasoactive intestinal polypeptide (VIP) is one of the most abundant molecules found in the respiratory tract. In human airways, it influences many respiratory functions via the receptors VPAC1, VPAC2 and PAC1. VIP-expressing nerve fibers are present in the tracheobronchial smooth muscle layer, submucosal glands and in the walls of pulmonary and bronchial arteries and veins. Next to its strong bronchodilator effects, VIP potently relaxes pulmonary vessels, and plays a pivotal role in the mediation of immune mechanisms. A therapy utilizing the respiratory effects of VIP would offer potential benefits in the treatment of obstructive and inflammatory diseases and long acting VIP-based synthetic non-peptide compounds may represent a novel target for drug development.
Keywords: VIP; Cytokine; Lung; Tachykinin

REGISTERED: Handelsregister Schwyz
COMPANY NUMBER: CH-1029-379-06
TAX NUMBER: 1029-379-06
Copyright © 2017. All Rights Reserved.
Institute for Biomodulation Medicine AG

SCHWERZISTRASSE 4, CH-8807 FREIENBACH (SZ)
PHONE: +41 41 5003753 FAX: +41 41 5003754
EMAIL: INFO@BIOMODULATION.ORG

logo

INSTITUTE FOR BIOMODULATION
MEDICINE

0.png0.png5.png6.png0.png3.png0.png1.png
Today175
Yesterday616
This week791
This month11746
Total560301

Tuesday, 20 August 2019 07:09